EGFR and non-small cell lung carcinoma: Similarly, changes in the expression of targets like epidermal growth factor receptor (EGFR) in non-small cell lung cancer can lead to resistance to EGFR inhibitors, as mutations or overexpression can alter drug binding, rendering the therapy less effective [69].